左旋咪唑作为一种免疫法的制剂与其它细菌免疫佐剂的区别就在于它并不刺激健康者的免疫反应超过正常水平。为数众多的动物和临床研究提示,左旋咪唑作为抗癌药物要获得理想的疗效就需达到临界剂量(2.5毫克/公斤体重/日—人体),这个剂量需与体重和体表相适应。此外,左旋咪唑看来对血行转移性肿瘤以及治疗前肿瘤负荷较重的患者效应最高,同时,由于大多数癌症对左旋咪唑的作用具有易感性,这种 Levamisole as an immunological preparation differs from other bacterial immunoadjuvants in that it does not stimulate the immune response of healthy individuals to exceed normal levels. A large number of animal and clinical studies suggest that levamisole as an anti-cancer drug needs to reach a critical dose (2.5 mg / kg bw / day - human body) to achieve the desired therapeutic effect. This dose should be adapted to body weight and body surface. In addition, levamisole appears to have the highest effect on patients with hematogenous metastases and patients with pre-treatment tumor burden, and because most cancers are susceptible to levamisole, this